<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00742001</url>
  </required_header>
  <id_info>
    <org_study_id>CTS-0040</org_study_id>
    <nct_id>NCT00742001</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Mirasol-Treated Whole Blood Red Cell Recovery and Survival</brief_title>
  <acronym>IMPROVE</acronym>
  <official_title>IMPROVE: Inactivation of Whole Blood With Mirasol (R): Performance in Red Blood Cells, Platelets and Plasma Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Terumo BCTbio</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Terumo BCTbio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility trial to evaluate recovery and survival of red blood cells (RBCs) from
      Mirasol-treated whole blood
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiolabeling of red blood cells (RBCs) followed by infusion back to the donor is commonly
      used to test the quality of RBCs in a person. By measuring the level of radioisotope in a
      blood sample, these tests evaluate what percentage of the RBCs remain in the bloodstream
      after 24 hours (recovery) and can predict how long the RBCs will remain in circulation
      (survival). The IMPROVE trial is a feasibility trial to evaluate these parameters in RBCs
      obtained from whole blood units that have been treated with the Mirasol System.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    An endpoint difference between 3 energies was not observed at interim analysis
  </why_stopped>
  <start_date type="Actual">September 10, 2008</start_date>
  <completion_date type="Actual">December 16, 2008</completion_date>
  <primary_completion_date type="Actual">November 20, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Red Blood Cell (RBC) Recovery</measure>
    <time_frame>24-hour post autologous infusion of RBCs</time_frame>
    <description>The 24-hour recovery calculation was conducted to evaluate the percentage of labeled RBCs remaining in the circulation 24 hours after re-infusion of the cells, as compared to Time 0 measurements (time of re-infusion). FDA requires at least 75% recovery for new RBC processes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predicted Total Lifespan of Red Blood Cells (RBCs), Based on 28-day RBC Survival</measure>
    <time_frame>28-days post autologous infusion of RBCs</time_frame>
    <description>The objective of measuring 28-day survival was to identify the potential total lifespan of labeled RBCs in circulation. Normal, native RBCs remain in circulation for a maximum of approximately 120 days; by using the 51Cr half-life of approximately 28 days, and its elution rate from labeled RBCs, the survival of the labeled cells can be predicted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of Participants With Serious Adverse Events (SAE)</measure>
    <time_frame>28-days post autologous infusion of RBCs</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Mirasol Illumination Dose #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole blood units treated with Mirasol at Illumination dose #1 (A1) of 22 Joules per milliliter of red blood cells (J/mL RBCs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirasol Illumination Dose #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole Blood units treated with Mirasol at Illumination dose #2 (A2) of 33 J/mL RBCs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mirasol Illumination Dose #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole Blood units treated with Mirasol at Illumination dose #3 (A3) of 44 J/mL RBCs</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mirasol System for Whole Blood.</intervention_name>
    <description>Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
    <arm_group_label>Mirasol Illumination Dose #1</arm_group_label>
    <arm_group_label>Mirasol Illumination Dose #2</arm_group_label>
    <arm_group_label>Mirasol Illumination Dose #3</arm_group_label>
    <other_name>Mirasol System</other_name>
    <other_name>Mirasol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy adults who meet AABB (formerly known as the American Association of Blood
             Banks) criteria for whole blood donation

          -  females incapable of becoming pregnant

          -  males agreeing to use contraception during trial

        Exclusion Criteria:

          -  pregnancy or nursing

          -  abnormal medical history (bleeding disorders, anemia, myocardial ischemia,
             uncontrolled hypertension, heart disease, epilepsy)

          -  major surgery

          -  use of drugs affecting coagulation or RBC function

          -  recent participation in other trials which may confound results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Cancelas-Perez, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati, Hoxworth Blood Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati, Hoxworth Blood Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 25, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2008</study_first_posted>
  <results_first_submitted>May 16, 2019</results_first_submitted>
  <results_first_submitted_qc>August 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>red blood cells</keyword>
  <keyword>transfusion</keyword>
  <keyword>recovery</keyword>
  <keyword>feasibility</keyword>
  <keyword>white blood cell inactivation</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mirasol Illumination Dose #1 (A1)</title>
          <description>Whole blood units treated with Mirasol at Illumination dose #1: 22 Joules per milliliter of red blood cells (J/mL RBC)
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
        </group>
        <group group_id="P2">
          <title>Mirasol Illumination Dose #2 (A2)</title>
          <description>Whole Blood units treated with Mirasol at Illumination dose #2: 33 J/mL RBC
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
        </group>
        <group group_id="P3">
          <title>Mirasol Illumination Dose #3 (A3)</title>
          <description>Whole Blood units treated with Mirasol at Illumination dose #3: 44 J/mL RBC
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawn; health exclusion (flu)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mirasol Illumination Dose #1 (A1)</title>
          <description>Whole blood units treated with Mirasol at Illumination dose #1: 22 J/mL RBC
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
        </group>
        <group group_id="B2">
          <title>Mirasol Illumination Dose #2 (A2)</title>
          <description>Whole Blood units treated with Mirasol at Illumination dose #2: 33 J/mL RBC
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
        </group>
        <group group_id="B3">
          <title>Mirasol Illumination Dose #3 (A3)</title>
          <description>Whole Blood units treated with Mirasol at Illumination dose #3: 44 J/mL RBC
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="7"/>
                    <measurement group_id="B2" value="42" spread="18"/>
                    <measurement group_id="B3" value="51" spread="13"/>
                    <measurement group_id="B4" value="46" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (inches)</title>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="4"/>
                    <measurement group_id="B2" value="70" spread="3"/>
                    <measurement group_id="B3" value="68" spread="3"/>
                    <measurement group_id="B4" value="69" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (lbs)</title>
          <units>lbs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219" spread="26"/>
                    <measurement group_id="B2" value="180" spread="17"/>
                    <measurement group_id="B3" value="253" spread="62"/>
                    <measurement group_id="B4" value="217" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pulse (bpm)</title>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="5"/>
                    <measurement group_id="B2" value="68" spread="3"/>
                    <measurement group_id="B3" value="72" spread="11"/>
                    <measurement group_id="B4" value="69" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure (mmHg)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123" spread="11"/>
                    <measurement group_id="B2" value="112" spread="11"/>
                    <measurement group_id="B3" value="122" spread="16"/>
                    <measurement group_id="B4" value="119" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic Blood Pressure (mmHg)</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76" spread="5"/>
                    <measurement group_id="B2" value="69" spread="7"/>
                    <measurement group_id="B3" value="76" spread="13"/>
                    <measurement group_id="B4" value="74" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oral Temperature degrees Fahrenheit (F)</title>
          <units>degrees Fahrenheit (F)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98" spread="0.6"/>
                    <measurement group_id="B2" value="97" spread="0.3"/>
                    <measurement group_id="B3" value="97" spread="0.4"/>
                    <measurement group_id="B4" value="97" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Red Blood Cell (RBC) Recovery</title>
        <description>The 24-hour recovery calculation was conducted to evaluate the percentage of labeled RBCs remaining in the circulation 24 hours after re-infusion of the cells, as compared to Time 0 measurements (time of re-infusion). FDA requires at least 75% recovery for new RBC processes.</description>
        <time_frame>24-hour post autologous infusion of RBCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mirasol Illumination Dose #1 (A1)</title>
            <description>Whole blood units treated with Mirasol at Illumination dose #1: 22 J/mL RBC
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
          </group>
          <group group_id="O2">
            <title>Mirasol Illumination Dose #2 (A2)</title>
            <description>Whole Blood units treated with Mirasol at Illumination dose #2: 33 J/mL RBC
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
          </group>
          <group group_id="O3">
            <title>Mirasol Illumination Dose #3 (A3)</title>
            <description>Whole Blood units treated with Mirasol at Illumination dose #3: 44 J/mL RBC
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Red Blood Cell (RBC) Recovery</title>
          <description>The 24-hour recovery calculation was conducted to evaluate the percentage of labeled RBCs remaining in the circulation 24 hours after re-infusion of the cells, as compared to Time 0 measurements (time of re-infusion). FDA requires at least 75% recovery for new RBC processes.</description>
          <units>percentage of recovered RBCs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" spread="3.4"/>
                    <measurement group_id="O2" value="70.5" spread="7.5"/>
                    <measurement group_id="O3" value="68.1" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Predicted Total Lifespan of Red Blood Cells (RBCs), Based on 28-day RBC Survival</title>
        <description>The objective of measuring 28-day survival was to identify the potential total lifespan of labeled RBCs in circulation. Normal, native RBCs remain in circulation for a maximum of approximately 120 days; by using the 51Cr half-life of approximately 28 days, and its elution rate from labeled RBCs, the survival of the labeled cells can be predicted.</description>
        <time_frame>28-days post autologous infusion of RBCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mirasol Illumination Dose #1 (A1)</title>
            <description>Whole blood units treated with Mirasol at Illumination dose #1.
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
          </group>
          <group group_id="O2">
            <title>Mirasol Illumination Dose #2 (A2)</title>
            <description>Whole Blood units treated with Mirasol at Illumination dose #2.
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
          </group>
          <group group_id="O3">
            <title>Mirasol Illumination Dose #3 (A3)</title>
            <description>Whole Blood units treated with Mirasol at Illumination dose #3.
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Predicted Total Lifespan of Red Blood Cells (RBCs), Based on 28-day RBC Survival</title>
          <description>The objective of measuring 28-day survival was to identify the potential total lifespan of labeled RBCs in circulation. Normal, native RBCs remain in circulation for a maximum of approximately 120 days; by using the 51Cr half-life of approximately 28 days, and its elution rate from labeled RBCs, the survival of the labeled cells can be predicted.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.9" spread="17.8"/>
                    <measurement group_id="O2" value="66.9" spread="31.0"/>
                    <measurement group_id="O3" value="55.9" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Count of Participants With Serious Adverse Events (SAE)</title>
        <time_frame>28-days post autologous infusion of RBCs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mirasol Illumination Dose #1 (A1)</title>
            <description>Whole blood units treated with Mirasol at Illumination dose #1.
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
          </group>
          <group group_id="O2">
            <title>Mirasol Illumination Dose #2 (A2)</title>
            <description>Whole Blood units treated with Mirasol at Illumination dose #2.
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
          </group>
          <group group_id="O3">
            <title>Mirasol Illumination Dose #3 (A3)</title>
            <description>Whole Blood units treated with Mirasol at Illumination dose #3.
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Count of Participants With Serious Adverse Events (SAE)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of autologous RBC re-infusion until study completion (28 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mirasol Illumination Dose #1 (A1)</title>
          <description>Whole blood units treated with Mirasol at Illumination dose #1: 22 J/mL RBC
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
        </group>
        <group group_id="E2">
          <title>Mirasol Illumination Dose #2 (A2)</title>
          <description>Whole Blood units treated with Mirasol at Illumination dose #2: 33 J/mL RBC
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
        </group>
        <group group_id="E3">
          <title>Mirasol Illumination Dose #3 (A3)</title>
          <description>Whole Blood units treated with Mirasol at Illumination dose #3: 44 J/mL RBC
Mirasol System for Whole Blood.: Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Slight heartburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Head stuffiness and congestion (allergy related)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cold, sore throat, sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Sinus infection and bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flu</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All publication of results and or design of this study are contingent upon approval from the sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Two major limitations to the interpretation of these data. 1)the small sample size limited the interpretation of some of the data. 2)the high degree of inter-subject variability further limits the interpretation of potential trends seen in the data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Marty Huntington / Sr Mgr Global Clinical Affairs</name_or_title>
      <organization>Terumo BCT</organization>
      <phone>+1 (303) 231-4849</phone>
      <email>Marty.Huntington@terumobct.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

